Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05114980 · ClinicalTrials.gov registry record · NA

Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism

A NA study, sponsored by University of Alabama at Birmingham.

Not yet
Registry status
NA
Development phase
5
Enrollment target

NCT05114980 is a NA study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05114980, a NA study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.

NOT YET RECRUITING
Registry status
NA
Development phase
5 participants
Enrollment target

Study Summary

Options for treatment of severe, refractory hypocalcemia are limited for the thousands of patients in the United States who suffer from hypoparathyroidism. Parathyroid allotransplantation is an emerging treatment that provides hope for these individuals. Currently, this therapy has only been successfully provided by a few centers in the world. In the UAB PATH trial, we propose to become one of the few centers worldwide to successfully achieve parathyroid allotransplantation in transplant-naïve patients.

Interventions

  • PROCEDURE Parathyroid Allotransplant

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2027-07
Est. Completion 2030-01
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT05114980

The ClinicalTrials.gov registry entry for NCT05114980 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Parathyroid Allotransplant is the first listed.

NCT05114980 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05114980 about?

NCT05114980 is a clinical study titled "Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism". Options for treatment of severe, refractory hypocalcemia are limited for the thousands of patients in the United States who suffer from hypoparathyroidism. Parathyroid allotransplantation is an emerging treatment that provides hope for these individuals. Currently, this therapy has only been success...

What is the current status of trial NCT05114980?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2027-07. Estimated completion is 2030-01.

What interventions are being tested in trial NCT05114980?

The interventions under investigation include: Parathyroid Allotransplant (PROCEDURE).

Who is sponsoring clinical trial NCT05114980?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.